Future work should include animal experimentation and clinical studies to assess whether pharmacological inhibition of 11β-HSD1 or GR antagonism may improve Nrf2-dependent cell defense and whether such intervention may be beneficial for ALD patients or for patients with chronic inflammation such as diabetes or rheumatoid arthritis. Here, NR3C1 is linked to diabetes mellitus.